Valiant Laboratories Ltd.

•

valiantorganics.comBSE: 543998NSE: VALIANTLAB

Market Cap₹ 692 Cr.

Current Price

High / Low₹ 130 / 50

Stock P/E52.4

Book Value₹ 61

Price to Book1.42

Dividend Yield0.00 %

ROCE-0.4 %

ROE-0.9 %

Face Value₹ 10

Add ratio to table

ABOUT

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence

50%

View full sector analysis →

PROS

Latest quarter profit grew 420.8% YoY, showing strong momentum
Strong cash generation - operating cash flow backs reported profits (CFO/PAT 1.83x)
Working capital cycle has improved - days down from 367 to 269
Company generates healthy free cash flow
Company maintains a comfortable, low leverage position

CONS

Company is loss-making at the operating / net level
Operating cash flow has been negative in recent years
Receivables are growing faster than sales - a possible quality concern
Interest coverage is weak at -7.3x - earnings barely cover interest
Company has a low return on capital employed of 8.5%

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs

Part ofNIFTY 50 NIFTY 500 NIFTY LARGEMIDCAP 250 NIFTY 100 NIFTY 200

S.No.	Name
1.	SUNPHARMA	1842.00	36.54	441957.50	0.87	2901.23	26.53	15299.88	10.98	19.11	28.81
2.	DIVISLAB	9326.00	84.64	247576.00	0.32	902.00	65.50	3080.00	27.80	21.51	40.75
3.	TORNTPHARM	4975.00	86.76	189233.01	0.76	566.00	3.28	4921.00	57.32	19.27	33.81
4.	ZYDUSLIFE	1119.50	24.74	111670.55	0.09	990.20	-34.90	8017.00	23.97	21.39	24.54
5.	CIPLA	1365.00	32.72	110272.68	0.95	785.55	-39.18	7119.28	4.13	16.00	16.73
6.	LAURUSLABS	1970.35	97.37	106460.42	0.10	362.07	123.94	2026.31	29.10	18.20	31.50
7.	DRREDDY	1161.00	30.07	96906.38	0.69	435.60	-69.10	8099.80	-5.21	13.75	10.63
8.	AUROPHARMA	1675.45	25.97	96401.69	0.24	1032.03	25.22	9150.35	17.44	12.76	20.54
9.	LUPIN	2096.00	17.34	95842.92	0.86	1416.98	16.01	8276.89	34.28	28.86	29.59
10.	MANKIND	2277.00	46.04	94050.37	0.04	574.09	29.12	4030.59	12.89	13.24	26.30
11.	GLENMARK	2416.90	37.94	68210.88	0.10	482.83	927.88	4018.48	31.35	20.35	20.03
12.	VALIANTLAB	127.48	43.26	692.38	0.00	21.10	1058.87	115.28	146.23	-0.40	25.38

Detailed Comparison with:

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	51	60	41	31	19	21	35	58	51	46	55	65	73
	48	61	47	35	21	28	35	54	49	46	54	61	62
Operating Profit	4	-1	-6	-5	-2	-7	1	4	2	0	0	4	12
OPM %	7.43%	-2.32%	-15.55%	-14.81%	-12.66%	-31.38%	1.76%	6.63%	4.63%	0.13%	0.46%	6.89%	16.17%
	2	3	2	2	2	2	1	1	1	1	1	1	1
Interest	0	0	0	0	0	0	0	0	0	0	0	0	0
Depreciation	0	0	0	0	0	1	1	1	1	1	1	1	1
Profit before Tax	6	1	-5	-3	-1	-5	1	4	2	0	0	5	13
Tax %	26.12%	25.47%	30.50%	52.16%	-29.87%	-12.41%	-122.22%	17.60%	25.71%	34.62%	72.73%	25.32%	25.53%
Net Profit	4	1	-4	-1	-1	-6	2	3	2	0	0	4	9
	1.31	0.24	-0.81	-0.32	-0.23	-1.39	0.37	0.74	0.42	0.03	0.01	0.65	1.75

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
	292	334	182	133	239
	249	299	190	138	223
Operating Profit	42	35	-8	-5	17
OPM %	14.52%	10.50%	-4.62%	-3.52%	6.97%
	2	5	10	5	3
Interest	0	0	0	0	0
Depreciation	2	2	2	2	2
Profit before Tax	42	38	-1	-1	18
Tax %	34.07%	23.96%	145.22%	-48.51%	25.89%
Net Profit	27	29	0	-2	13
EPS	9.52	8.91	0.08	-0.49	—
Dividend Payout %	0.00%	0.00%	0.00%	0.00%	—

COMPOUNDED SALES GROWTH

10 Years:: —
5 Years:: —
3 Years:: -23%

COMPOUNDED PROFIT GROWTH

10 Years:: —
5 Years:: —
3 Years:: —

STOCK PRICE CAGR

10 Years:: —
5 Years:: —
3 Years:: —
1 Year:: 49%

RETURN ON EQUITY

10 Years:: —
5 Years:: —
3 Years:: 11%
Last Year:: -1%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	16	33	43	43
	55	68	193	191
	62	61	61	61
Trade Payables	46	47	25	19
	2	4	2	3
Total Liabilities	182	213	325	317
	22	30	32	30
Capital Work in Progress	1	0	0	0
	0	34	119	165
	16	13	10	4
	0	0	46	72
Cash & Bank	20	0	97	27
	122	135	22	19
Total Assets	182	213	325	317

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2022	Mar 2023	Mar 2024	Mar 2025
	17	32	49	-22
Cash from Investing	-12	-21	-183	25
Cash from Financing	6	-2	136	-1
	-4	0	2	3

Ratios

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2022	Mar 2023	Mar 2024	Mar 2025

Shareholding Pattern

Numbers in percentages

	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	74.94	74.94	74.94	74.94	74.94	74.94	74.94	74.94	74.94
	1.89	0.00	0.00	0.64	0.63	0.02	0.01	0.20	0.00
DIIs	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Government	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	23.17	25.06	25.06	24.42	24.43	25.04	25.05	24.86	25.06

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

2026-09-04

Copy of Newspaper Publication

2026-09-04 - Valiant Laboratories Limited has informed the Exchange regarding Dispatch of Annual Report for FY 2025-26 and Notice of 5th Annual General Meeting to the members of the Company.

2026-09-03

Credit Rating

2026-09-03 - Valiant Laboratories Limited has informed the Exchange about Credit Rating

2026-09-03

General Updates

2026-09-03 - Valiant Laboratories Limited has informed the Exchange 'Letter to shareholders under Regulation 36(1)(b) of SEBI (LODR) Regulations 2015'.

2026-09-03

Shareholders meeting

2026-09-03 - Valiant Laboratories Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 28, 2026 and the Annual Report for the FY 2025-26

2026-08-31

Copy of Newspaper Publication

2026-08-31 - Valiant Laboratories Limited has informed the Exchange about Copy of Newspaper Publication w.r.t. 5th AGM of the Company

2026-08-12

Copy of Newspaper Publication

2026-08-12 - Valiant Laboratories Limited has informed the Exchange about Copy of Newspaper Publication

2026-08-10

Monitoring Agency Report

2026-08-10 - Monitoring Agency Report for quarter ended June 30, 2026

2026-08-10

Address Change

2026-08-10 - Valiant Laboratories Limited has informed the Exchange regarding change in Corporate Office of the company.

2026-08-10

Address Change

2026-08-10 - Valiant Laboratories Limited has informed the Exchange regarding change in Registered Office of the company.

News

Recent coverage and analyst commentary for VALIANTLAB

Loading news…

🤖

AI Stock Analyst

Valiant Laboratories Ltd.

🔒

Sign in to Chat with AI

✨ Sign In to Chat

Free 5nance Account

Name

SUNPHARMA

1842.00

36.54

441957.50

0.87

2901.23

26.53

15299.88

10.98

19.11

28.81

DIVISLAB

9326.00

84.64

247576.00

0.32

902.00

65.50

3080.00

27.80

21.51

40.75

TORNTPHARM

4975.00

86.76

189233.01

0.76

566.00

3.28

4921.00

57.32

19.27

33.81

ZYDUSLIFE

1119.50

24.74

111670.55

0.09

990.20

-34.90

8017.00

23.97

21.39

24.54

CIPLA

1365.00

32.72

110272.68

0.95

785.55

-39.18

7119.28

4.13

16.00

16.73

LAURUSLABS

1970.35

97.37

106460.42

0.10

362.07

123.94

2026.31

29.10

18.20

31.50

DRREDDY

1161.00

30.07

96906.38

0.69

435.60

-69.10

8099.80

-5.21

13.75

10.63

AUROPHARMA

1675.45

25.97

96401.69

0.24

1032.03

25.22

9150.35

17.44

12.76

20.54

LUPIN

2096.00

17.34

95842.92

0.86

1416.98

16.01

8276.89

34.28

28.86

29.59

MANKIND

2277.00

46.04

94050.37

0.04

574.09

29.12

4030.59

12.89

13.24

26.30

GLENMARK

2416.90

37.94

68210.88

0.10

482.83

927.88

4018.48

31.35

20.35

20.03

VALIANTLAB

127.48

43.26

692.38

0.00

21.10

1058.87

115.28

146.23

-0.40

25.38

Jun 2023

Sep 2023

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Jun 2026

Operating Profit

-1

-6

-5

-2

-7

OPM %

7.43%

-2.32%

-15.55%

-14.81%

-12.66%

-31.38%

1.76%

6.63%

4.63%

0.13%

0.46%

6.89%

16.17%

Interest

Depreciation

Profit before Tax

-5

-3

-1

-5

Tax %

26.12%

25.47%

30.50%

52.16%

-29.87%

-12.41%

-122.22%

17.60%

25.71%

34.62%

72.73%

25.32%

25.53%

Net Profit

-4

-1

-6

1.31

0.24

-0.81

-0.32

-0.23

-1.39

0.37

0.74

0.42

0.03

0.01

0.65

1.75

Mar 2022

Mar 2023

Mar 2024

Mar 2025

TTM

292

334

182

133

239

249

299

190

138

223

Operating Profit

-8

-5

OPM %

14.52%

10.50%

-4.62%

-3.52%

6.97%

Interest

Depreciation

Profit before Tax

-1

Tax %

34.07%

23.96%

145.22%

-48.51%

25.89%

Net Profit

-2

EPS

9.52

8.91

0.08

-0.49

—

Dividend Payout %

0.00%

—

Mar 2022

Mar 2023

Mar 2024

Mar 2025

Equity Capital

193

191

Trade Payables

Total Liabilities

182

213

325

317

Capital Work in Progress

119

165

Cash & Bank

122

135

Total Assets

182

213

325

317

Mar 2022

Mar 2023

Mar 2024

Mar 2025

-22

Cash from Investing

-12

-21

-183

Cash from Financing

-2

136

-1

-4

Mar 2022

Mar 2023

Mar 2024

Mar 2025

Jun 2024

Sep 2024

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Jun 2026

74.94

1.89

0.00

0.64

0.63

0.02

0.01

0.20

0.00

DIIs

0.00

Government

0.00

23.17

25.06

24.42

24.43

25.04

25.05

24.86

25.06

Valiant Laboratories Ltd.

AI Sector View

Peer comparison

Quarterly Results

Profit & Loss

Balance Sheet

Corporate actions

Cash Flows

Ratios

Shareholding Pattern

Documents

News

Sign in to Chat with AI

Valiant Laboratories Ltd.

AI Sector View

Peer comparison

Quarterly Results

Profit & Loss

Balance Sheet

Corporate actions

Cash Flows

Ratios

Shareholding Pattern

Documents

News

Sign in to Chat with AI